Oxford Researchers Develop Promising Ovarian Cancer Vaccine

The OvarianVax aims to prevent ovarian cancer by training the immune system to target early-stage cancer cells, potentially saving thousands of lives.

OvarianVax, the world's first ovarian cancer vaccine, is being developed by scientists at the University of Oxford.
The vaccine works by teaching the immune system to recognize and attack proteins on early-stage ovarian cancer cells.
Clinical trials are planned, focusing initially on women with BRCA gene mutations, who are at higher risk for ovarian cancer.
The development is funded by Cancer Research UK, with hopes to see an impact within the next five years.
If successful, the vaccine could prevent the need for preventive surgeries in high-risk women and eventually be available to the general population.